Efficacy and safety of paliperidone palmitate 3-month versus 1-month formulation in patients with schizophrenia: comparison between European and non-European population

QR Code

Efficacy and safety of paliperidone palmitate 3-month versus 1-month formulation in patients with schizophrenia: comparison between European and non-European population

Adam J Savitz,1 Haiyan Xu,1 Srihari Gopal,1 Isaac Nuamah,1 Paulien Ravenstijn,2 David Hough,1 Ludger Hargarter3 1Janssen Research & Development, LLC, Raritan, NJ, USA; 2Janssen Research & Development, a Division of Janssen Pharmaceutica NV, Beerse, Belgium; 3Medical & Scient...

Description complète

Enregistré dans:

Détails bibliographiques
Auteurs principaux:	Savitz AJ, Xu H, Gopal S, Nuamah I, Ravenstijn P, Hough D, Hargarter L
Format:	article
Langue:	EN
Publié:	Dove Medical Press 2019
Sujets:	long-acting injectable non-inferiority randomized relapse tolerability Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Accès en ligne:	https://doaj.org/article/2e783d06a91c488f9fb5a86eeb213adf
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires

Predictors of achieving remission in schizophrenia patients treated with paliperidone palmitate 3-month formulation
par: Nash AI, et autres
Publié: (2019)

Efficacy and safety of paliperidone palmitate three-monthly formulation in East Asian patients with schizophrenia: subgroup analysis of a global, randomized, double-blind, Phase III, noninferiority study
par: Savitz AJ, et autres
Publié: (2017)

Clinical relevance of paliperidone palmitate 3-monthly in treating schizophrenia
par: Mathews M, et autres
Publié: (2019)

Time to onset and time to resolution of extrapyramidal symptoms in patients with exacerbated schizophrenia treated with 3-monthly vs once-monthly paliperidone palmitate
par: Mathews M, et autres
Publié: (2018)

Transitioning from Once-Monthly to Once-Every-3-Months Paliperidone Palmitate Among Veterans with Schizophrenia
par: El Khoury AC, et autres
Publié: (2021)

Defining “Adequately Treated”: A Post Hoc Analysis Examining Characteristics of Patients with Schizophrenia Successfully Transitioned from Once-Monthly Paliperidone Palmitate to Once-Every-3-Months Paliperidone Palmitate
par: O'Donnell A, et autres
Publié: (2021)

Comparison of Relapse Prevention with 3 Different Paliperidone Formulations in Patients with Schizophrenia Continuing versus Discontinuing Active Antipsychotic Treatment: A Post-Hoc Analysis of 3 Similarly Designed Randomized Studies
par: Mathews M, et autres
Publié: (2020)

Long-term efficacy and safety of paliperidone palmitate once-monthly in Chinese patients with recent-onset schizophrenia
par: Si T, et autres
Publié: (2019)

Safety and efficacy of paliperidone palmitate 1-month formulation in Chinese patients with schizophrenia: a 25-week, open-label, multicenter, Phase IV study
par: Zhao JP, et autres
Publié: (2017)

Role of paliperidone palmitate 3-monthly in the management of schizophrenia: insights from clinical practice
par: Lopez A, et autres
Publié: (2019)

Once-monthly paliperidone palmitate in early stage schizophrenia – a retrospective, non-interventional 1-year study of patients with newly diagnosed schizophrenia
par: Emsley R, et autres
Publié: (2017)

Impact of time of initiation of once-monthly paliperidone palmitate in hospitalized Asian patients with acute exacerbation of schizophrenia: a post hoc analysis from the PREVAIL study
par: Li H, et autres
Publié: (2018)

Online Survey of Clinical Practice in Patients with Schizophrenia Treated with Long-Acting Injectable Aripiprazole or Paliperidone Palmitate
par: Such P, et autres
Publié: (2021)

Taiwan Expert Consensus Recommendations for Switching to Aripiprazole Long-Acting Once-Monthly in Patients with Schizophrenia
par: Chih-Sung Liang, et autres
Publié: (2021)

Effect of Paliperidone Palmitate 3-Month Formulation on Goal Attainment and Disability After 52 Weeks’ Treatment in Patients with Clinically Stable Schizophrenia
par: Lambert M, et autres
Publié: (2020)

Role of 3-monthly long-acting injectable paliperidone in the maintenance of schizophrenia
par: Brasso C, et autres
Publié: (2017)

Long-term tolerability of once-monthly injectable paliperidone palmitate in subjects with recently diagnosed schizophrenia
par: Sliwa JK, et autres
Publié: (2012)

Improvement of Negative Symptoms in Schizophrenia with Paliperidone Palmitate 1-Month and 3-Month Long-Acting Injectables: Results from a Phase 3 Non-Inferiority Study
par: Gopal S, et autres
Publié: (2020)

Long-lasting extrapyramidal symptoms after multiple injections of paliperidone palmitate to treat schizophrenia
par: Takada R, et autres
Publié: (2018)

Once-monthly paliperidone injection for the treatment of schizophrenia
par: Delia Bishara
Publié: (2010)

Efficacy and safety profile of paliperidone palmitate injections in the management of patients with schizophrenia: an evidence-based review
par: Emsley R, et autres
Publié: (2018)

Caregiver burden in schizophrenia following paliperidone palmitate long acting injectables treatment: pooled analysis of two double-blind randomized phase three studies
par: Srihari Gopal, et autres
Publié: (2017)

Effectiveness of 1-year treatment with long-acting formulation of aripiprazole, haloperidol, or paliperidone in patients with schizophrenia: retrospective study in a real-world clinical setting
par: Di Lorenzo R, et autres
Publié: (2019)

Number needed to treat and number needed to harm with paliperidone palmitate relative to long-acting haloperidol, bromperidol, and fluphenazine decanoate for treatment of patients with schizophrenia
par: Srihari Gopal, et autres
Publié: (2011)

Efficacy and safety of once-monthly injection of paliperidone palmitate in hospitalized Asian patients with acute exacerbated schizophrenia: an open-label, prospective, noncomparative study
par: Li HF, et autres
Publié: (2015)

Factors related to improvement of symptoms, function, and caregiver burden in Chinese patients with schizophrenia after switching to paliperidone palmitate once-monthly from oral antipsychotics
par: Li N, et autres
Publié: (2018)

Symptomatic stability with aripiprazole once-monthly: efficacy analyses from acute and long-term studies
par: Madera JJ, et autres
Publié: (2019)

Expansion of guidance for the day 8 initiation dose of paliperidone palmitate to avoid a missed dose
par: Samtani MN, et autres
Publié: (2013)

Incidence and time course of extrapyramidal symptoms with oral and long-acting injectable paliperidone: a posthoc pooled analysis of seven randomized controlled studies
par: Gopal S, et autres
Publié: (2013)

Efficacy, safety, and impact on hospitalizations of paliperidone palmitate in recent-onset schizophrenia
par: Zhang F, et autres
Publié: (2015)

Efficacy and safety of risperidone long-acting injection in elderly people with schizophrenia
par: Dhiren Singh, et autres
Publié: (2009)

The effect of aripiprazole once-monthly on personal and social functioning: post hoc analyses of acute and long-term studies
par: Peters-Strickland T, et autres
Publié: (2019)

Long-Acting Injectable Drugs in the Maintenance Therapy of Patients with Schizophrenia
par: Natalia N. Petrova, et autres
Publié: (2020)

Ethanol-Wet Bonding Technique: 18-month Clinical Evaluation
par: Barros,Thaís Andrade De Figueiredo, et autres
Publié: (2016)

Therapeutic efficacy of monthly subcutaneous injection of daclizumab in relapsing multiple sclerosis
par: Cohan S
Publié: (2016)

Treatment of Patients with Recently Exacerbated Schizophrenia with Paliperidone Palmitate: A Pilot Study of Efficacy and Tolerability
par: Gattaz WF, et autres
Publié: (2020)

Comparison of Weight Gain in Injectable Contraceptive 1-Month And 3-Month Acceptors at The Independent Midwife Practice Tambaksari Surabaya
par: Khoiriya Ardiani, et autres
Publié: (2020)

Attitudes and Willingness to Accept Long-Acting Injections for Patients With Schizophrenia in Beijing: A Cross-Sectional Investigation Based on Samples From the Communities
par: Junli Zhu, et autres
Publié: (2021)

THE CORRELATION BETWEEN FAMILY SUPPORT AND RELAPSE IN SCHIZOPHRENIA AT THE PSYCHIATRIC HOSPITAL
par: Rostime Hermayerni Simanullang
Publié: (2018)

Use of the Functioning Assessment Short Test (FAST) in defining functional recovery in bipolar I disorder. Post-hoc analyses of long-term studies of aripiprazole once monthly as maintenance treatment
par: Madera J, et autres
Publié: (2019)